AMETEK said net sales for Q2 2025 were $1,778.1 million, an increase of $43.3 million or 2.5%, and orders were $1,782.1 million, an increase of $104.9 million or 6.3%. The company cited a 2% increase from acquisitions and a 1% effect of foreign currency translation as factors in the net sales increase.

1. 01

   AMETEK said net sales for Q2 2025 were $1,778.1 million, an increase of $43.3 million or 2.5%, and orders were $1,782.1 million, an increase of $104.9 million or 6.3%. The company cited a 2% increase from acquisitions and a 1% effect of foreign currency translation as factors in the net sales increase.

2. 02

   AMETEK said consolidated operating income for Q2 2025 was $461.6 million, or 26.0% of net sales, an increase of $14.1 million or 3.2%, and diluted earnings per share were $1.55, an increase of $0.10 or 6.9%. The company explained that operating margins were negatively impacted by a 20 basis points dilutive impact of recent acquisitions and 50 basis points of foreign currency translation headwinds.

3. 03

   AMETEK said EIG net sales for Q2 2025 were $1,159.6 million, reflecting a 0.5% increase from acquisitions and a 3% organic sales decrease, and operating income was $344.4 million, a 1.6% decrease. EMG net sales were $618.5 million, reflecting a 6.4% increase from acquisitions and a 5% organic sales increase, and operating income was $143.9 million, an increase of 16.9%.

4. 04

   AMETEK said cash provided by operating activities for the first six months of 2025 was $776.6 million, a decrease of $15.1 million or 1.9%, and cited higher working capital investments as the primary factor. The company said it acquired all outstanding shares of FARO Technologies common stock in July 2025 for approximately $920.0 million, net of cash acquired.

Key figures

Quarter ended June 30, 2025

Revenue

$1.8B

Operating income

$462M

Net income

$358M

EPS

$1.55

Analysis scope · Management's discussion (MD&A)We analyzed the Management's Discussion and Analysis (MD&A) section. Other sections of the report, such as the notes to the financial statements and risk factors, were not reviewed.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.